University of Pittsburgh MACS/WIHS CCS
- Institution
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA
- Principal investigator
- Charles R Rinaldo
- Funding
- $4.0M
- Duration
- 2019–2026
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY/ABSTRACT The overarching strategy of the University of Pittsburgh (Pitt) clinical research site (CRS) together with our collaborative clinical site at The Ohio State University (OSU) of the Multicenter AIDS Cohort Study (MACS)/Woman’s Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS CCS) is to support, complement and accelerate the CCS unified scientific agenda (USA) by leveraging the strengths and scientific expertise of CRS investigators. We propose to continue to expand on our 35 years of extensive research on the natural history of HIV infection. The central hypothesis of this grant application is that, as men and women with chronic HIV infection age, they increase their risks for serious, life-shortening comorbidities beyond those of comparable age, uninfected persons, and this could differ between men and women. As directed by NIH RFA- HL-19-008, the CRS will provide robust and inclusive leadership focused on five specific aims of the USA, and targeted collaborative support for the five other aims, to improve our understanding of the epidemiologic, clinical, virologic, immunologic, and behavioral relationships of HIV infection to chronic comorbidities in men and women that represent the current HIV epidemic in the United States. The CRS will also contribute longitudinal data and biological specimens for collaborative research projects on HIV led by CCS and non-CCS investigators. This research is important to fulfill our mission of improving clinical management, increasing survival and controlling, preventing and curing HIV infection. The CRS will provide the most current and innovative epidemiological, clinical and laboratory methods and psychosocial research protocols to accomplish our 5 leadership specific aims. The Pitt/OSU CRS will be led by a triumvirate of MPIs and several CoIs with broad expertise needed to lead five highly specialized CCS USA Specific Aims (Aim 2: Pulmonary/Sleep [Morris]; Aim 3: Neurocognitive [Becker]; Aim 6: HIV/Pathogenesis [Macatangay]; Aim 7: Psychosocial [Stall]; Aim 9: Platform [Rinaldo, Kingsley]) and to provide insight for the 5 other Specific Aims (Aim 1: Cardiovascular [Kingsley, Martinson], Aim 4: Aging [Koletar], Aim 5: Cancer [Jenkins], Aim 8: Health Disparities [Krier], Aim 10: Career Development [Sluis- Cremer]. With this plan the Pitt/OSU CRS addresses the basic justification of the FOA, i.e., that the impact of HIV, its treatment, and the legacy of immune suppression need to be more fully understood to optimize the health of people living with HIV.
Research team
- Jeremy James MartinsonPI
- Charles R RinaldoPI
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of Pittsburgh at PittsburghNot yet scored
Immune response to COVID-19 vaccine in HIV infected men and women
Robbie B Mailliard · $712K · 2021–2026
- NIH · University of Pittsburgh at Pittsburgh64
Core E: Omics Core
Sid E O'Bryant · $3.2M · 2020–2026
- NIH · University of Pittsburgh at Pittsburgh60
Project 3: Biomarkers for DS Clinical Trials
Sid E O'Bryant · $148K · 2020–2026